BIO International Convention 2022 shared the latest insights into diversity, equity and inclusion (DEI) in the biotechnology industry this week.
List view / Grid view
Sanofi’s new Diversity, Equity & Inclusion (DE&I) Board, and accompanying global Employee Resource Group (ERG) framework, will support the delivery of the company’s DE&I strategy.
Dr William Pao will assume his role as Executive Vice President and Chief Development Officer at Pfizer in March 2022, replaced at Roche by Dr Hans Clevers.
Bristol Myers Squibb (BMS)’s Tomorrow’s Innovators programme will promote the recruitment of Black talent into the biopharma industry.
Bayer have announced that Professor Dominik Ruettinger will be its new Head of Research and Early Development for Oncology, effective 1 October 2021.
Scientists, administrators, staff and leaders at the NIH have laid out their framework under the UNITE initiative to end structural racism in the biomedical industry.
Researchers suggest, based on certain exclusions, older people are likely to be underrepresented in 50 percent of COVID-19 trials and all vaccine trials in the US.
Pharma executives are committed to bringing drugs to market to improve the lives of patients but is the industry too introspective to be truly innovative?
Professor Gillian Leng has been appointed as the new Chief Executive of NICE and will take over from Sir Andrew Dillon in early April.
New research has revealed that despite a rising number of women in STEM publishing papers, there is a large gender difference due to females leaving academia.